Design Considerations for Macroencapsulation Devices for Stem Cell Derived Islets for the Treatment of Type 1 Diabetes

Goswami D, Domingo-Lopez DA, Ward NA, Millman JR, Duffy GP, Dolan EB, Roche ET

View at source ↗PDF ↗Review41 citations

Abstract

Stem cell derived insulin producing cells or islets have shown promise in reversing Type 1 Diabetes (T1D), yet successful transplantation currently necessitates long-term modulation with immunosuppressant drugs. An alternative approach to avoiding this immune response is to utilize an islet macroencapsulation device, where islets are incorporated into a selectively permeable membrane that can protect the transplanted cells from acute host response, whilst enabling delivery of insulin. These macroencapsulation systems have to meet a number of stringent and challenging design criteria in order to achieve the ultimate goal of reversing T1D. In this progress report, the design considerations and functional requirements of macroencapsulation systems are reviewed, specifically for stem-cell derived islets (SC-islets), highlighting distinct design parameters. Additionally, a perspective on the future for macroencapsulation systems is given, and how incorporating continuous sensing and closed-loop feedback can be transformative in advancing toward an autonomous biohybrid artificial pancreas.

Abstract of "Design Considerations for Macroencapsulation Devices for Stem Cell Derived Islets for the Treatment of Type 1 Diabetes" by Goswami D, Domingo-Lopez DA, Ward NA et al., https://doi.org/10.1002/advs.202100820, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.

Record

Archive ID
doi:10.1002/advs.202100820
Published
Jun 21, 2021
Venue
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
DOI
10.1002/advs.202100820
PubMed
34155834
PMC
PMC8373111
License
CC-BY
Provenance
europepmc

Topics